NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and Licensing Agreement for NKT2152 in Greater China

– NiKang will receive an upfront cash payment of $15 million, up to $203 million in potential future milestones and tiered royalties on net sales

– Hansoh will lead the development and commercialization of NKT2152 in Greater China

WILMINGTON, Del.–(BUSINESS WIRE)– NiKang Therapeutics Inc. (“NiKang”), a clinical-stage biotechnology company focused on developing innovative small molecule oncology drugs to help patients with unmet medical needs and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, 3692.HK), a leading biopharmaceutical company based in China and the United States, today announced an exclusive collaboration and license agreement for the development and commercialization of NKT2152, for the treatment of cancer in Greater China, including mainland China, Hong Kong, Macao and Taiwan.

“Hansoh is a leader in the development and commercialization of small molecules for the treatment of cancer in China. We are excited to collaborate with them to strategically advance NKT2152 and expand its reach as a potential treatment for multiple tumor types,” said Zhenhai Gao, Ph.D., co-founder, chairman and CEO of NiKang. “By combining NiKang’s precision oncology expertise with Hansoh’s proven development and commercialization capabilities in Greater China, we believe we will be able to accelerate the global development of NKT2152 and bring it to market sooner. potential new cancer treatment to Chinese patients.

“We are delighted to enter into this agreement and look forward to working with NiKang, a leader in the development of innovative small molecule oncology drugs,” said Yuan Sun, Executive Director of the Board of Hansoh Pharma. “HIF2α plays an important role in the development and progression of kidney cancers and other cancers. Based on the sound biology, excellent potency and PK profile seen in preclinical studies, we believe that NKT2152 has the potential to become a first-in-class molecule to address this important pathway. Our extensive expertise in oncology drug development can help accelerate development and advance NKT2152 as quickly as possible for cancer patients in China. »

Under the terms of the agreement, NiKang will receive an upfront cash payment of $15 million and may receive up to $203 million in potential development, regulatory and sales-based milestone payments, and tiered royalties. . Hansoh will be responsible for all development costs of NKT2152 in Greater China and will receive exclusive rights to develop and commercialize NKT2152 in the region.

About NKT2152

NKT2152 is a small molecule that inhibits HIF2α. It is currently undergoing a Phase 1/2 dose escalation and expansion trial (NCT05119335). This trial is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity in patients with advanced cCRC.

About NiKang Therapeutics

NiKang Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule oncology drugs to help patients with unmet medical needs. Our target selection is guided by in-depth knowledge of disease biology and molecular pathways. Our discovery approach is informed by the biology of the target structure and capitalizes on structure-based drug design. The successful execution of our strategy enables us to discover and advance proprietary medicines quickly and efficiently. For more information, visit www.nikangtx.com.

About Hansoh Pharmaceutical Group Company Limited

Hansoh Pharma (3692.HK), one of the largest biopharmaceutical companies in China, is committed to discovering and developing life-changing medicines to help patients overcome serious diseases and disorders. Hansoh Pharma is supported by a total of 12,150 dedicated employees in China and the United States.

Founded in 1995, Hansoh Pharma has fully integrated research and development, manufacturing and commercial capabilities, supporting leadership positions in a wide range of therapeutic areas, including oncology, central nervous system (CNS) disorders, infectious diseases, metabolic diseases and other main therapeutics. areas. With the support of approximately 1,650 highly skilled R&D professionals, Hansoh Pharma has successfully developed several in-house discovered drug candidates into NMPA-approved breakthrough drugs, including Aumolertinib (Ameile®, 阿美乐®), a third-generation EGFR inhibitor for the treatment of NSCLC with EGFR mutations; Flumatinib (Xinfu®, 昕福®), a second-generation BCR-ABL inhibitor for the first-line treatment of chronic myeloid leukemia (CML); PEG-Loxenatide (Fulaimei®, 孚来美®), the first long-acting once-weekly GLP-1 analog discovered and developed in China for the treatment of diabetes; Morinidazole (Mailingda®, 迈灵达®), a third-generation nitroimidazole antibiotic; and tenofovir amibufenamide (Hengmu®, 恒沐®), the first second-generation oral anti-HBV developed in China. Through collaboration and partnership, the NMPA has granted approval to Inebilizumab (Xinyue®, 昕越®), a humanized anti-CD19 monoclonal antibody, as a treatment for patients with neuromyelitis optica spectrum disorder (NMOSD). For more information, please visit www.hspharm.com.

Comments are closed.